Amolyt Pharma Closes $138M Series C Round Of Financing
Therapeutics company Amolyt Pharma, which focuses on rare endocrine and related diseases, announced Friday it closed its $138 million Series C equity financing that it will use to complete clinical developments....To view the full article, register now.
Already a subscriber? Click here to view full article